Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME. · 2004

Read Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? by Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2409471.txt.

Introduction

Ross and colleagues asked whether weight loss worsens chemotherapy results in lung cancers in 2004. They used records collected from 1994 to 2001 for three diseases treated with chemotherapy: small-cell lung cancer, advanced non-small-cell lung cancer, and mesothelioma, a cancer of the lung lining. The groups held 290, 418, and 72 patients.

Weight loss was common: 59% of small-cell patients, 58% of non-small-cell patients, and 76% of mesothelioma patients reported it. Those patients more often failed to finish three treatment cycles and had fewer symptom improvements. In non-small-cell cancer they also suffered more anaemia, a drop in red blood cells. After adjustment, weight loss independently predicted shorter survival in all three diseases. The risk of death ran 1.5 times higher in small-cell cancer and 1.92 times higher in mesothelioma for weight-losing patients.

Catalog record

CREATORRoss PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2409471

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? By P J Ross, S Ashley, A Norton, K Priest, J S Waters, T Eisen, I E Smith, M E R O'Brien Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6601781 ABSTRACT Abstract To examine whether weight loss at presentation influences outcome in patients who received chemotherapy for lung cancer or mesothelioma. Multivariate analysis of prospectively collected data 1994–2001. Data were available for age, gender, performance status, histology, stage, response, toxicity, progression-free and overall survival. The outcomes of patients with or without weight loss treated with chemotherapy for small cell lung cancer (SCLC; n=290), stages III and IV non-small-cell lung cancer (NSCLC; n=418), or mesothelioma (n=72) were compared. Weight loss was reported by 59, 58 and 76% of patients with SCLC, NSCLC and mesothelioma, respectively. Patients with weight loss and NSCLC (P=0.003) or mesothelioma (P=0.05) more frequently failed to complete at least three cycles of chemotherapy. Anaemia as a toxicity occurred significantly more frequently in NSCLC patients with weight loss (P=0.0003). The incidence of other toxicities was not significantly affected by weight loss. NSCLC patients with weight loss had fewer symptomatic responses (P=0.001). Mesothelioma patients with weight loss had fewer symptomatic (P=0.03) and objective responses (P=0.05). Weight loss was an independent predictor of shorter overall survival for patients with SCLC (P=0.003, relative risk (RR)=1.5), NSCLC (P=0.009, RR=1.33) and mesothelioma (P=0.03, RR=1.92) and an independent predictor of progression-free survival in patients with SCLC (P=0.01, RR=1.43). In conclusion, weight loss as a symptom of lung cancer predicts for toxicity from treatment and shorter survival. Keywords: weight loss, non-small-cell lung cancer, small cell lung cancer, mesothelioma Lung cancer is the most common cancer globally with more than 1 million new cases recorded each year (Cancer Research Campaign, 2001). Approximately three-quarters of patients have non-small-cell lung cancer (NSCLC), with small cell lung cancer (SCLC) accounting for the other quarter. Survival for patients with both NSCLC and SCLC remains dismal with less than 5% of patients with NSCLC alive at 5 years and a median survival of 6–10 months for patients presenting with stage IIIB or IV disease (Cullen et al, 1999; Bonomi et al, 2000; Kelly et al, 2001; Smith et al, 2001). Similarly, the majority of patients with SCLC die within 18 months of presentation. Mesothelioma currently accounts for 10 000 deaths worldwide and this number is predicted to increase until at least 2020 (Peto et al, 1995). Survival is poor with a median of between 4 and 18 months in most series. In patients with lung cancer and mesothelioma, weight loss is common at presentation and a frequent cause of patient concern. Weight loss is the result of an imbalance between energy intake and energy expenditure. Some studies have reported elevated resting energy expenditure in patients with solid cancers (Fredrix et al, 1991; Hyltander et al, 1991; Staal-van den Brekel et al, 1994, 1995). It was suggested that this increase is more pronounced in weight-losing patients and consequently hyper-metabolism contributed to weight loss. However, other studies have not confirmed such an increase in resting energy expenditure (Melville et al, 1990; Jatoi et al, 1999). Hyper-metabolism and weight loss have both been associated with the presence of enhanced levels of inflammatory mediators and acute phase proteins in NSCLC (Staal-van den Brekel et al, 1995; Simons et al, 1999). However, it is not known why only some tumours should result in hyper-metabolism. Many other factors may contribute to weight loss in patients with cancer, including nausea and vomiting, constipation, diarrhoea, pain, altered taste and depression, all of which may be iatrogenic or due to the cancer. Several studies have indicated that weight loss at presentation may be an independent prognostic variable of outcome in both NSCLC and SCLC (Dewys et al, 1980; Stanley, 1980; Ray et al, 1998; Martins and Pereira, 1999; Tas et al, 1999), but it has not been clearly shown why this might be the case. Previous studies have not addressed whether patients with weight loss have more aggressive disease than patients without weight loss. An alternative explanation is that weight loss is associated with reduced tolerance of chemotherapy, increased toxicity and the administration of less chemotherapy overall. The Lung Unit of the Royal Marsden Hospital (RMH) has been treating patients with NSCLC, SCLC and mesothelioma with chemotherapy over many years. This study aimed to assess whether weight loss at presentation had an influence on the toxicity patients suffered from during chemotherapy, and on whether weight loss altered the amount of chemotherapy delivered. In addition, we aimed to assess whether stabilisation of weight during treatment had any effect on outcome. PATIENTS AND METHODS Patients This study reviewed data that had been recorded prospectively on the RMH lung unit research database between 1994 and March 2001 for patients with SCLC, stage III or IV NSCLC, or mesothelioma and treated with chemotherapy. Patients were excluded if their weight loss status at presentation was unknown or the patient did not receive a standard chemotherapy regimen within 2 months of presentation. Further exclusion criteria included prior radiotherapy and prior adjuvant or palliative chemotherapy. Patients were permitted to have radiotherapy following chemotherapy, but this variable was not included in the analysis Patients who stated they had lost weight at the time of presentation were compared to those who denied weight loss. Parameters measured included objective and symptomatic response, treatment-related toxicity, progression free and overall survival. Within the group who had lost weight at presentation, those with continuing measured weight loss during chemotherapy were compared with those in whom weight stabilised or increased during the first 63 days of treatment. The rationale for a 63 day period for this assessment is that patients treated for NSCLC are currently treated with three cycles of chemotherapy following the findings of Smith et al (2001) that survival was similar for patients treated with three or six cycles of mitomycin, vinblastine and cisplatin (MVP). Patients were not given dietary advice or recommended to take dietary supplements. Patient assessment Weight loss at presentation was established and recorded by direct questioning of the patient during a preliminary assessment by the doctor at their first attendance at the RMH. Patients were asked whether they had lost any weight since their illness began. Patients who reported weight loss were asked whether they knew their weight prior to the illness; by comparison with measured weight the extent of weight loss was estimated (less than or greater than 10% of preillness weight). Patients were weighed on each attendance for chemotherapy and at the outpatient clinic. Objective response to treatment was classified using the WHO/UICC response criteria following serial CT scans every 6 weeks and chest X-rays every 3 weeks (WHO, 1979). Symptoms were established by direct questioning and any change in symptoms compared to baseline was recorded on each attendance. Response of a symptom to treatment was defined as improvement in a particular symptom maintained for at least 3 weeks. Performance status was recorded at baseline and at each attendance. Toxicity was graded according to WHO toxicity criteria (WHO, 1979) by direct questioning, physical examination and measurement of full blood count, urea and electrolytes, and liver function tests. Treatment Chemotherapeutic regimen depended on

Read the complete text